Agendia Inc.

Irvine,  CA 
United States
http://www.agendia.com

• Booth: 3100a

Agendia is committed to improving clinical outcomes and informing the journey for patients with early stage breast cancer. MammaPrint®, the 70-gene breast cancer recurrence assay, is the first FDA-cleared risk-of-recurrence test backed by peer-reviewed, prospective outcome data and included in both national and international guidelines. BluePrint®, the 80-gene molecular subtyping assay, evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make informed treatment decisions. Agendia’s assays can be ordered on core biopsies or surgical specimens with results in as little as 5-7 days to inform pre- and post-operative treatment decisions. Learn more: www.agendia.com

Brands: https://events.jspargo.com/ASCO21/CUSTOM/Agendia%20ASCO%20Booth%20Banner%20(1)%20(002).png

 Show Specials

• 3-Patient Documentary (Apr 27, 2021)
  <iframe width="1280" height="720" src="https://www.youtube.com/embed/nikIsmXl4_s" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>

• Agendia Corporate Overview Video (Apr 27, 2021)
  <iframe width="1280" height="720" src="https://www.youtube.com/embed/zwwngxoZoI4" title="YouTube video player" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture" allowfullscreen></iframe>

 Press Releases

• Core Bx Collateral (Apr 23, 2021)
  https://agendia.com/M-USA-314-V12021MAR-Core-Bx-Collateral-/

• MammaPrint + BluePrint Overview (Apr 28, 2021)
  https://agendia.com/m-usa-309-v1-2021feb-mp-bp-overview-1_/

• Pathology Brochure (Apr 28, 2021)
  https://agendia.com/digital-page-by-page-m-usa-303-v1-17x11-path-brochure-1/

• Patient Brochure (Apr 28, 2021)
  https://agendia.com/agendia_brochure_v11/

• US Test Request Form (TRF) (Apr 28, 2021)
  https://agendia.com/wp-content/uploads/2021/03/M-USA-008-V7_USTRF-1.pdf

• Miami pCR Poster (Apr 28, 2021)
  https://agendia.com/pathologic-complete-response-pcr-rates-according-to-mammaprint-and-blueprint-results-are-consistent-among-pre-and-post-menopausal-patients/

• 5-year outcome in the NBRST Trial (Apr 28, 2021)
  https://agendia.com/?s=nbrst&post_type%5B%5D=post&fs=1

• APHINITY trial (Apr 28, 2021)
  https://agendia.com/prediction-of-benefit-from-adjuvant-pertuzumab-by-blueprint-rna-sequencing-in-the-aphinity-trial/

• Product Brochure (Apr 28, 2021)
  https://agendia.com/m-usa-308-v2_agendia-12-page-brochure/

• FLEX SABCS 2020 (Apr 29, 2021)
  https://agendia.com/2020_sabcs_tip_final/

 Products